Last reviewed · How we verify
intravenous levetireacetam
Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release.
Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release. Used for Adjunctive therapy for partial-onset seizures, Adjunctive therapy for myoclonic seizures in patients with juvenile myoclonic epilepsy, Adjunctive therapy for primary generalized tonic-clonic seizures.
At a glance
| Generic name | intravenous levetireacetam |
|---|---|
| Sponsor | ayesha tariq |
| Drug class | Antiepileptic agent |
| Target | SV2A (synaptic vesicle protein 2A) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Levetiracetam is a pyrrolidone derivative that binds to the synaptic vesicle protein SV2A, which is involved in vesicle exocytosis and neurotransmitter release. This binding reduces the release of excitatory neurotransmitters and stabilizes neuronal membranes, thereby suppressing seizure propagation. The exact mechanism remains incompletely understood, but SV2A binding is considered the primary molecular action responsible for its anticonvulsant effects.
Approved indications
- Adjunctive therapy for partial-onset seizures
- Adjunctive therapy for myoclonic seizures in patients with juvenile myoclonic epilepsy
- Adjunctive therapy for primary generalized tonic-clonic seizures
Common side effects
- Somnolence
- Asthenia/fatigue
- Dizziness
- Headache
- Behavioral/mood changes
- Infection
- Ataxia
Key clinical trials
- Comparison of Efficacy of Phenytoin With Levetireacetam for the Management of Children With Status Epilepticus (PHASE4)
- Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravenous levetireacetam CI brief — competitive landscape report
- intravenous levetireacetam updates RSS · CI watch RSS
- ayesha tariq portfolio CI